1. Home
  2. ROIV vs ILMN Comparison

ROIV vs ILMN Comparison

Compare ROIV & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$28.58

Market Cap

20.7B

Sector

Health Care

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$124.93

Market Cap

20.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROIV
ILMN
Founded
2014
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.7B
20.4B
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
ROIV
ILMN
Price
$28.58
$124.93
Analyst Decision
Strong Buy
Hold
Analyst Count
8
17
Target Price
$27.56
$124.24
AVG Volume (30 Days)
6.3M
2.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
170.87
EPS
N/A
5.45
Revenue
$29,053,000.00
$4,343,000,000.00
Revenue This Year
N/A
$6.52
Revenue Next Year
$385.85
$5.49
P/E Ratio
N/A
$23.52
Revenue Growth
N/A
N/A
52 Week Low
$8.73
$68.70
52 Week High
$30.03
$155.53

Technical Indicators

Market Signals
Indicator
ROIV
ILMN
Relative Strength Index (RSI) 63.29 44.37
Support Level $20.46 $124.27
Resistance Level N/A $126.00
Average True Range (ATR) 0.95 4.36
MACD -0.00 1.22
Stochastic Oscillator 66.80 49.94

Price Performance

Historical Comparison
ROIV
ILMN

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: